Not Signed In - Dynavax Reports Positive Phase 2a NHL Data At ASH Meeting
Mon, 11 Dec 2006 08:00 AM EST
... Dynavax Technologies Corporation (Nasdaq: DVAX) announced today preliminary data from an ongoing open label Phase 2a study of the company's TLR9 agonist used in combination with rituximab as a treatment for patients with non-Hodgkin's lymphoma. The results were reported this morning by Dr. Jonathan W. Friedberg, M.D. of the James P. [click link for full article] ...
Related Topics
- Data & Statistics
- Data Analysis
- National Data
- Interferon Alfa-2a
- Mining
- Peginterferon alfa-2a
- Dilation And Curettage
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Tb
- Well Baby Reports
- Logging
- Tuberculosis Surveillance Reports
- Chronic Disease At A Glance Reports
- Chronic Disease Notes And Reports
- Sexually Transmitted Disease Surveillance Reports
- Vaccine Safety and Adverse Event Reports
- Chemical Safety
- Visualization
- Influenza Surveillance Data
email this page
print this page
bookmark this page
feedback on this page
